HZNP has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
HZNP has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.
For the three months ended in Jun. 2023, Horizon Therapeutics's Net Income From Continuing Operations was $127 Mil. Its Depreciation, Depletion and Amortization was $96 Mil. Its Change In Working Capital was $-111 Mil. Its cash flow from deferred tax was $-5 Mil. Its Cash from Discontinued Operating Activities was $0 Mil. Its Asset Impairment Charge was $0 Mil. Its Stock Based Compensation was $60 Mil. And its Cash Flow from Others was $-6 Mil. In all, Horizon Therapeutics's Cash Flow from Operations for the three months ended in Jun. 2023 was $161 Mil.
The historical data trend for Horizon Therapeutics's Cash Flow from Operations can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Horizon Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||||
Cash Flow from Operations | Get a 7-Day Free Trial | 194.54 | 426.33 | 555.69 | 1,035.27 | 1,257.84 |
Horizon Therapeutics Quarterly Data | ||||||||||||||||||||
Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | |
Cash Flow from Operations | Get a 7-Day Free Trial | 249.20 | 366.46 | 426.39 | 86.32 | 161.47 |
Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.
Horizon Therapeutics's Cash Flow from Operations for the fiscal year that ended in Dec. 2022 is calculated as:
Cash Flow from Operations | (A: Dec. 2022 ) | ||||||
= | Net Income From Continuing Operations | + | Depreciation, Depletion and Amortization | + | Change In Working Capital | + | Deferred Tax |
= | 521.482 | + | 390.393 | + | -11.98 | + | 49.814 |
+ | Cash from Discontinued Operating Activities | + | Asset Impairment Charge | + | Stock Based Compensation | + | Cash Flow from Others |
+ | 0 | + | 56.171 | + | 182.1 | + | 69.862 |
= | 1,258 |
Horizon Therapeutics's Cash Flow from Operations for the quarter that ended in Jun. 2023 is:
Cash Flow from Operations | (Q: Jun. 2023 ) | ||||||
= | Net Income From Continuing Operations | + | Depreciation, Depletion and Amortization | + | Change In Working Capital | + | Deferred Tax |
= | 127.071 | + | 96.285 | + | -111.118 | + | -4.642 |
+ | Cash from Discontinued Operating Activities | + | Asset Impairment Charge | + | Stock Based Compensation | + | Cash Flow from Others |
+ | 0 | + | 0 | + | 60.27 | + | -6.4 |
= | 161 |
Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,041 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Horizon Therapeutics (NAS:HZNP) Cash Flow from Operations Explanation
For companies reported in indirect method, cash flow from operations contains six items:
1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.
Horizon Therapeutics's net income from continuing operations for the three months ended in Jun. 2023 was $127 Mil.
2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets
Horizon Therapeutics's depreciation, depletion and amortization for the three months ended in Jun. 2023 was $96 Mil.
3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.
Horizon Therapeutics's change in working capital for the three months ended in Jun. 2023 was $-111 Mil. It means Horizon Therapeutics's working capital declined by $111 Mil from Mar. 2023 to Jun. 2023 .
4. Deferred Tax:
It is the cash flow generated from deferred tax.
Horizon Therapeutics's cash flow from deferred tax for the three months ended in Jun. 2023 was $-5 Mil.
5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.
Horizon Therapeutics's cash from discontinued operating Activities for the three months ended in Jun. 2023 was $0 Mil.
6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.
Horizon Therapeutics's asset impairment charge for the three months ended in Jun. 2023 was $0 Mil.
7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.
Horizon Therapeutics's stock based compensation for the three months ended in Jun. 2023 was $60 Mil.
8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).
Horizon Therapeutics's cash flow from others for the three months ended in Jun. 2023 was $-6 Mil.
Thank you for viewing the detailed overview of Horizon Therapeutics's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.
Andy Pasternak | officer: EVP and Chief Business Officer | C/O HORIZON THERAPEUTICS PLC, CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD, DUBLIN L2 D04 C5Y6 |
Aaron Cox | officer: EVP, Chief Financial Officer | C/O HORIZON THERAPEUTICS PLC, 70 ST. STEPHEN'S GREEN, DUBLIN L2 D02 E2X4 |
Jeffrey W Sherman | officer: EVP & Chief Medical Officer | C/O IDM PHARMA, INC., 9 PARKER, SUITE 100, IRVINE CA 92618 |
Patrick Mcilvenny | officer: Chief Accounting Officer | C/O HORIZON THERAPEUTICS PLC, 70 ST. STEPHEN'S GREEN, DUBLIN L2 D02 E2X4 |
Sean M. Clayton | officer: EVP, General Counsel | C/O HORIZON THERAPEUTICS PLC, 70 SAINT STEPHENS GREEN, DUBLIN L2 D02 E2X4 |
Thompson Elizabeth H.z. | officer: EVP, Research & Development | C/O HORIZON THERAPEUTICS, INC., 2 TOWER PLACE, 12TH FLOOR, SOUTH SAN FRANCISCO CA 94080 |
Timothy P Walbert | director, officer: President, Chairman and CEO | 1033 SKOKIE BOULEVARD, SUITE 355, NORTHBROOK IL 60062 |
Jacopo Leonardi | officer: Chief Commercial Officer | C/O HORIZON THERAPEUTICS PLC, 70 ST. STEPHEN'S GREEN, DUBLIN L2 D02 E2X4 |
Paul W. Hoelscher | officer: EVP Finance | 1 HORIZON WAY, C/O HORIZON THERAPEUTICS, INC., DEERFIELD IL 60015 |
Michael A. Desjardin | officer: EVP, Technical Operations | C/O JAZZ PHARMACEUTICALS, INC., 3180 PORTER DRIVE, PALO ALTO CA 94304 |
Miles W Mchugh | officer: Principal Accounting Officer | C/O ACCRETIVE HEALTH, INC., 401 N. MICHIGAN AVE, SUITE 2700, CHICAGO IL 60611 |
Barry Moze | officer: EVP, Corporate Dev't. | C/O HORIZON PHARMA, INC., 520 EAST COOK ROAD, SUITE 520, DEERFIELD IL 60015 |
Brian K Beeler | officer: EVP, General Counsel | C/O HORIZON PHARMA PLC, 520 LAKE COOK ROAD, SUITE 520, DEERFIELD IL 60015 |
Michael G Grey | director | C/O SGX PHARMACEUTICALS, INC., 10505 ROSELLE STREET, SAN DIEGO CA 92121 |
William F Daniel | director | TREASURY BUILDING, LOWER GRAND CANAL STREET, DUBLIN 2 L2 00000 |
From GuruFocus
By Business Wire • 09-13-2023
By Business Wire • 07-28-2023
By Business Wire • 09-25-2023
By Business Wire • 10-03-2023
By Business Wire • 09-29-2023
By GuruFocus Research • 11-15-2023
By Business Wire • 07-28-2023
By Business Wire • 09-29-2023
By PRNewswire • 09-13-2023
By GuruFocus Research • 11-14-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.